Mercer Global Advisors’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Mercer Global Advisors's IBRX Position: Q3 2026 in Review
Mercer Global Advisors increased its ImmunityBio (IBRX) stake by 33% in Q3 2026, buying an estimated $36.2K and bringing the position to 18,373 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3468.
Mercer Global Advisors first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Mercer Global Advisors held 18,373 shares of ImmunityBio worth $173K as of Q3 2026.
- Mercer Global Advisors bought 4,525 ImmunityBio shares in Q3 2026, an estimated $36.2K.
- ImmunityBio made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #3468 holding.
- Mercer Global Advisors first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.